Abstract Number: 0840 • ACR Convergence 2025
Shared and Distinct Urinary Proteomic Signatures of Lupus Nephritis and Other Glomerular Diseases
Background/Purpose: Urine collects the byproducts of kidney biology and has emerged as a valuable, noninvasive source of molecular information that reflects intrarenal pathology. In lupus…Abstract Number: 0508 • ACR Convergence 2025
Serum immune complexes assessed using a cell-reporter assay are associated with serum IFN-alpha levels, disease activity and the risk of incident lymphoma in the ASSESS prospective cohort
Background/Purpose: Fc‐gamma receptor (FcγR) activation by soluble IgG immune complexes (sICs) is considered to play a pivotal pathogenic role in B-cell-mediated autoimmune diseases, such as…Abstract Number: 0299 • ACR Convergence 2025
Interpreting Myositis Autoantibody Line-Blot Immunoassays in Real-World Settings: Implications for Diagnostic Accuracy for Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) present with diverse clinical features and disease courses. The myositis autoantibody line blot immunoassay (LIA) has advanced IIM diagnostics and…Abstract Number: 1510 • ACR Convergence 2025
Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease result in substantial organs or systems damage or even fatal. The estimated number of global…Abstract Number: L11 • ACR Convergence 2024
Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification
Background/Purpose: Antinuclear antibody (ANA) immunofluorescence (IFA) patterns and titers are a key part of rheumatology diagnostics, however, there is considerable intra- and inter-laboratory variability with…Abstract Number: 0319 • ACR Convergence 2024
Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis
Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…Abstract Number: 0491 • ACR Convergence 2024
Small Molecule Metabolites, Potential Disease-specific Biomarkers for Predicting Treatment Response in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a complex chronic inflammatory condition primarily affecting joints, presenting a challenge in understanding its causes, varied subtypes, diagnostic indicators, and…Abstract Number: 0636 • ACR Convergence 2024
Evaluation of Clinical, Histological and Biomarker Response After Induction Treatment of Lupus Nephritis (LN)
Background/Purpose: LN occurrs in 50 to 75 percent of SLE patients and is associated with a significant morbimortality. LN presents distinct severity, with frequent flares…Abstract Number: 0738 • ACR Convergence 2024
Quantitative Vascular US Has Additional Diagnostic and Prognostic Value in GCA
Background/Purpose: Vascular Ultrasound (VUS) performs well in diagnosing Giant Cell Arteritis (GCA) but its role in monitoring disease activity and in predicting outcomes is unknown…Abstract Number: 0871 • ACR Convergence 2024
Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”
Background/Purpose: Rheumatoid arthritis (RA) is an chronic inflammatory disease that is frequently treated with tumor necrosis factor inhibitors (TNFi). Little is known about predictors of…Abstract Number: 1121 • ACR Convergence 2024
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated Rheumatic Diseases
Background/Purpose: AMG 329 (formerly HZN-1116), a human monoclonal antibody (mAb), binds to soluble and membrane-bound human feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand…Abstract Number: 1359 • ACR Convergence 2024
Association of Coronary Artery Calcium Score and Growth Differentiation Factor 15 in Rheumatoid Arthritis
Background/Purpose: Cardiovascular diseases are the leading cause of death in RA patients [Gravallese EM, Firestein GS. N Engl J Med. 2023;388:529-42]. However, risk calculation has…Abstract Number: 1642 • ACR Convergence 2024
A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
Background/Purpose: Achieving an NIH Activity Index of < 2 upon treatment is associated with less LN flare and thus better long-term kidney survival. Here, we…Abstract Number: 1849 • ACR Convergence 2024
Selective Targeting of One-Carbon Metabolism to Combat Rheumatoid Arthritis
Background/Purpose: Rapidly proliferating cells fuel their increased nucleotide demand by boosting one-carbon metabolism, associated with the survival of pathogenic proliferative cells and the release of…Abstract Number: 2233 • ACR Convergence 2024
Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
Background/Purpose: Studies have found autoantibodies (Ab) directed against heterogeneous nuclear ribonucleoprotein A2/B1 (anti-RA33), peptidyl arginine deiminase 4 (anti-PAD4) and carbamylated proteins (anti-CarP) each have diagnostic…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 109
- Next Page »
